search
Back to results

Bioequivalence Study of Naproxen Sodium 220 mg & Pseudoephedrine HCl 120 mg ER Tablets of Dr. Reddy's Under Fed Conditions

Primary Purpose

Healthy

Status
Completed
Phase
Phase 1
Locations
India
Study Type
Interventional
Intervention
Naproxen Sodium & Pseudoephedrine HCl
Sponsored by
Dr. Reddy's Laboratories Limited
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Healthy focused on measuring Bioequivalence, Crossover, Naproxen Sodium and Pseudoephedrine Hydrochloride

Eligibility Criteria

18 Years - 45 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Subjects must fulfill all of the following criteria to be considered for inclusion into this study:

  • Subjects will provide written informed consent.
  • Subjects must be healthy human beings within 18-45 years of age (inclusive) weighing at least 50 kg.
  • Subjects must be within ±15% of ideal body weight in relation to height according to Life Insurance Corporation of India height-weight chart for non- medical cases.
  • Subjects must be of normal health as determined by medical history and physical examination performed within 21 days prior to the commencement of the study.
  • Have normal ECG, X-ray and vital signs.
  • Availability of subject for the entire study period and willingness to adhere to protocol requirements as evidenced by written informed consent.

If subject is a female volunteer and

  • Is of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies. diaphragm,intrauterine device (IUD), or abstinence.
  • Is postmenopausal for at least 1 year.
  • Is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject.

Exclusion Criteria:

The subjects will be excluded under following conditions:

History or presence of significant:

  • Cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine,immunologic, dermatologic, musculoskeletal, neurological or psychiatric disease.
  • Alcohol dependence, alcohol abuse or drug abuse within past one year.
  • Moderate to heavy smoking (>10 cigarettes/day) or consumption of tobacco products.
  • Asthma, urticaria or other allergic type reactions after taking any medication.

Subjects who through completion of the study, would have donated in excess of

  • 500 ml of blood in 14 days, or
  • 500 - 800ml of blood in 14 days (unless approved by the Principal Investigator)
  • 1000 ml of blood in 90 days
  • 1250 ml of blood in 120 days
  • 1500 ml of blood in 180 days
  • 2000 ml of blood in 270 days
  • 2500 ml of blood in 1 year

Subjects who have participated in another clinical trial within 3 months of study start.

Subjects who have:

  • Systolic blood pressure less than 90 mm of Hg and higher than 150 mm of Hg
  • Diastolic blood pressure less than 60 mm of Hg and more than 95 mm of Hg. Minor deviations (1-3 mm Hg) at check-in may be acceptable at the discretion of the physician/investigator.
  • Pulse rate below 50/min. and above 105/min. Female volunteers demonstrating a positive pregnancy screen or currently breast-feeding.

Sites / Locations

  • Lotus Labs Private Limited

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Naproxen Sodium & Pseudoephedrine HCl

Aleve Cold and Sinus

Arm Description

Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg ER Tablets of Dr. Reddy's Laboratories.

Aleve Cold and Sinus(Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets).

Outcomes

Primary Outcome Measures

Bioequivalence based on Cmax and AUC parameters

Secondary Outcome Measures

Full Information

First Posted
May 26, 2010
Last Updated
June 11, 2010
Sponsor
Dr. Reddy's Laboratories Limited
search

1. Study Identification

Unique Protocol Identification Number
NCT01131767
Brief Title
Bioequivalence Study of Naproxen Sodium 220 mg & Pseudoephedrine HCl 120 mg ER Tablets of Dr. Reddy's Under Fed Conditions
Official Title
A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of Naproxen Sodium 220 mg + Pseudoephedrine HCL 120 mg ER Tablets and Aleve Cold and Sinus® Under Fed Conditions.
Study Type
Interventional

2. Study Status

Record Verification Date
June 2010
Overall Recruitment Status
Completed
Study Start Date
July 2004 (undefined)
Primary Completion Date
August 2004 (Actual)
Study Completion Date
September 2004 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Dr. Reddy's Laboratories Limited

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to assess the bioequivalence of Naproxen sodium 220 mg + Pseudoephedrine Hydrochloride 120 mg Extended Release tablets of with Aleve Cold and Sinus in healthy adult human subjects, under fed conditions.
Detailed Description
Open randomized, two treatment, two period, two sequence, single dose, crossover study of 26 healthy human adult subjects under fed conditions with a washout period of 27 days.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy
Keywords
Bioequivalence, Crossover, Naproxen Sodium and Pseudoephedrine Hydrochloride

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
26 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Naproxen Sodium & Pseudoephedrine HCl
Arm Type
Experimental
Arm Description
Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg ER Tablets of Dr. Reddy's Laboratories.
Arm Title
Aleve Cold and Sinus
Arm Type
Active Comparator
Arm Description
Aleve Cold and Sinus(Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets).
Intervention Type
Drug
Intervention Name(s)
Naproxen Sodium & Pseudoephedrine HCl
Other Intervention Name(s)
Aleve Cold and Sinus
Intervention Description
Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets
Primary Outcome Measure Information:
Title
Bioequivalence based on Cmax and AUC parameters
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Subjects must fulfill all of the following criteria to be considered for inclusion into this study: Subjects will provide written informed consent. Subjects must be healthy human beings within 18-45 years of age (inclusive) weighing at least 50 kg. Subjects must be within ±15% of ideal body weight in relation to height according to Life Insurance Corporation of India height-weight chart for non- medical cases. Subjects must be of normal health as determined by medical history and physical examination performed within 21 days prior to the commencement of the study. Have normal ECG, X-ray and vital signs. Availability of subject for the entire study period and willingness to adhere to protocol requirements as evidenced by written informed consent. If subject is a female volunteer and Is of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies. diaphragm,intrauterine device (IUD), or abstinence. Is postmenopausal for at least 1 year. Is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject. Exclusion Criteria: The subjects will be excluded under following conditions: History or presence of significant: Cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine,immunologic, dermatologic, musculoskeletal, neurological or psychiatric disease. Alcohol dependence, alcohol abuse or drug abuse within past one year. Moderate to heavy smoking (>10 cigarettes/day) or consumption of tobacco products. Asthma, urticaria or other allergic type reactions after taking any medication. Subjects who through completion of the study, would have donated in excess of 500 ml of blood in 14 days, or 500 - 800ml of blood in 14 days (unless approved by the Principal Investigator) 1000 ml of blood in 90 days 1250 ml of blood in 120 days 1500 ml of blood in 180 days 2000 ml of blood in 270 days 2500 ml of blood in 1 year Subjects who have participated in another clinical trial within 3 months of study start. Subjects who have: Systolic blood pressure less than 90 mm of Hg and higher than 150 mm of Hg Diastolic blood pressure less than 60 mm of Hg and more than 95 mm of Hg. Minor deviations (1-3 mm Hg) at check-in may be acceptable at the discretion of the physician/investigator. Pulse rate below 50/min. and above 105/min. Female volunteers demonstrating a positive pregnancy screen or currently breast-feeding.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sandhya Ravi, MBBS, MS.
Organizational Affiliation
Lotus Labs Pvt. Ltd.,
Official's Role
Principal Investigator
Facility Information:
Facility Name
Lotus Labs Private Limited
City
Bangalore
State/Province
Karnataka
ZIP/Postal Code
560034
Country
India

12. IPD Sharing Statement

Learn more about this trial

Bioequivalence Study of Naproxen Sodium 220 mg & Pseudoephedrine HCl 120 mg ER Tablets of Dr. Reddy's Under Fed Conditions

We'll reach out to this number within 24 hrs